The global bisoprolol market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Bisoprolol is a beta-blocker. It affects the heart and circulation of blood flow through arteries and veins and is used for the treatment of hypertension (high blood pressure). The major factor driving the demand for bisoprolol is the increasing prevalence of hypertension across the globe. According to the Center for Disease Control and Prevention, nearly half of adults or 47%, or 116 million have hypertension which is defined as a systolic blood pressure greater than 130 mmHg or diastolic blood pressure greater than 80 mmHg or are taking medication for hypertension in the US. Additionally, about 1 in 4 adults (24%) with hypertension have their condition under control, and about half of the adults or 45% or 37 million with uncontrolled hypertension have a blood pressure of 140/90 mmHg or higher in the US. Furthermore, about 34 million adults are recommended to take medication and about two out of three of this group or 19 million have a blood pressure of 140/90 mmHg or higher. Hence, the increasing prevalence of hypertension is driving the demand for bisoprolol for treatment which in turn is driving the growth of the market. 

Some major players in the market include Novartis International AG, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in January 2022, Glenmark announced that it has received final approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg from the US Food & Drug Administration (FDA). It is the generic version of Ziac1 Tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg, of Teva Pharmaceutical.

`Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Novartis International AG, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd., among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Bisoprolol Market Report by Segment

By Type

• Capsule

• Tablet

By Application 

• High Blood Pressure

• Angina pectoris

• Coronary Heart Disease

• Others

Global Bisoprolol Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa